Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607095 · ClinicalTrials.gov registry record · Phase 1
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
A Phase 1 study of Melanoma and Metastatic Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05607095: Recruiting Phase 1 study of Melanoma and Metastatic Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05607095 is a Phase 1 study of Melanoma and Metastatic Melanoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607095, a Phase 1 study of Melanoma and Metastatic Melanoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
Primary Outcome
Safety will be measured descriptively using CTCAE v5.0 for all patients who undergo surgical excision.
Conditions Studied
Interventions
- BIOLOGICAL Lifileucel (LN-144/LN-145)
Study Locations (2)
New York
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 1 |
What NCT05607095 shows while recruiting
NCT05607095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Lifileucel (LN-144/LN-145) is the first listed.
NCT05607095 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05607095 about?
NCT05607095 is a clinical study titled "A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma". This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
What is the current status of trial NCT05607095?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-11-01. Estimated completion is 2026-05-01.
What conditions does trial NCT05607095 study?
This clinical trial studies the following conditions: Melanoma, Metastatic Melanoma, Uveal Melanoma, Metastatic Uveal Melanoma.
What interventions are being tested in trial NCT05607095?
The interventions under investigation include: Lifileucel (LN-144/LN-145) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05607095?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607095 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05607095's enrollment target sits among peer trials
30 197th of 266 higher than 63 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI